Oct 23, 2019
Rigel Pharmaceuticals Provides Business Update Prior to Investor & Analyst Call
Oct 18, 2019
Rigel Receives Positive Trend Vote from CHMP for Fostamatinib Disodium Hexahydrate for Adult Patients with Chronic Immune Thrombocytopenia (ITP) in Europe
Oct 18, 2019
Nplate® (romiplostim) Now Approved For Earlier Use In Adults With Immune Thrombocytopenia
Sep 23, 2019
Rigel's fostamatinib Enters Phase 3 Clinical Trial in Japan with Kissei Pharmaceuticals for the Treatment of Chronic Immune Thrombocytopenia
Sep 16, 2019
China Recombinant Human Thrombopoietin Markets, 2013-2017, 2017-2018 & 2019-2023
Aug 06, 2019
Rigel Announces Second Quarter 2019 Financial Results and Provides Business Update
Jun 13, 2019
Rigel to Present Two Posters Highlighting Fostamatinib at the 24 Congress of the European Hematology Association (EHA)
May 30, 2019
Rare Disease Patient Candace Lerman Calls for Clinical Trials on Off-Label Treatments; Launches ITP Patient Driven Research Initiative
May 16, 2019
Rigel Enrolls First Patient in Phase 3 Clinical Trial of Fostamatinib Disodium Hexahydrate in Warm Autoimmune Hemolytic Anemia
Feb 28, 2019
Rigel Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Company Update
Jan 23, 2019
Rigel Pharmaceuticals Enters Collaboration and License Agreement with Grifols, S.A. to Commercialize Fostamatinib in Europe
Jan 07, 2019
Rigel Pharmaceuticals Provides Business Update
Dec 14, 2018
FDA Approves Nplate® (Romiplostim) For Use In Pediatric Patients With Immune Thrombocytopenia
Dec 02, 2018
Real-world data show Novartis drug Promacta® improves outcomes for ITP patients compared to other second-line therapies
Nov 15, 2018
Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics - Worldwide Market Analysis & Outlook to 2023: Key Players are Amgen, Bristol-Myers Squibb, Eisai, Merck Sharp & Dohme, and Novartis
Nov 08, 2018
U.S. Intravenous Immunoglobulin (IVIG) Market Analysis & Outlook (2018-2025): Stringent Regulations Pertaining to Production & Approval is Hampering Growth
Nov 06, 2018
Rigel Announces Third Quarter 2018 Financial Results and Provides Company Update
Nov 01, 2018
Rigel to Present Data on Fostamatinib in Three Presentations at the 60th American Society of Hematology Annual Meeting & Exposition
Oct 29, 2018
Rigel Pharmaceuticals Enters Collaboration and License Agreement with Kissei Pharmaceutical Co., Ltd. to Develop and Commercialize TAVALISSE(TM) (fostamatinib disodium hexahydrate) in Japan and other Asian Countries
Oct 18, 2018
UCB Accelerates Anti-FcRn Rozanolixizumab in Myasthenia Gravis Into Confirmatory Development Phase